DiaCarta Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Reverse Merger
  • (Cancelled)

  • Latest Deal Amount
  • $584M

  • Investors
  • 4

DiaCarta General Information

Description

Developer of detection tools designed for cancer diagnosis, therapy identification, and prognosis monitoring. The company's tools offer a range of cancer diagnostics and IVD products specialized in genomic testing for biomarkers and also offer clinical sample testing services apart from oncology along with COVID-19 testing services, enabling healthcare practitioners to provide improved care to patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Corporate Office
  • 4385 Hopyard Road
  • Suite 100
  • Pleasanton, CA 94588
  • United States
+1 (800) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DiaCarta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Reverse Merger 13-Oct-2022 $584M Cancelled Generating Revenue
4. Debt - PPP 14-May-2020 00000 0000 Completed Generating Revenue
3. Grant 17-Sep-2018 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series B) 12-Feb-2018 $45M $53M Completed Generating Revenue
1. Early Stage VC (Series A) 09-Jan-2015 $8M $8M Completed Generating Revenue
To view DiaCarta’s complete valuation and funding history, request access »

DiaCarta Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of detection tools designed for cancer diagnosis, therapy identification, and prognosis monitoring. The compan
Laboratory Services (Healthcare)
Pleasanton, CA
49 As of 2024
0000
000000000000

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
0000000000 00000000
Miami, FL
000 As of 0000
00.000 0000-00-00
000000&0

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000000000000
Wuxi, China
00000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiaCarta Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Igenomix Formerly PE-Backed Miami, FL 000 000000&0
GeneCast Biotechnology Private Equity-Backed Wuxi, China 00000 00000000
Ambry Genetics Corporate Backed or Acquired Aliso Viejo, CA 000 000000&0
Biodesix Formerly VC-backed Louisville, CO 000 00000 000000000 00000
Biocept Formerly VC-backed San Diego, CA 00 00000 000000000000 00000
You’re viewing 5 of 51 competitors. Get the full list »

DiaCarta Patents

DiaCarta Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4136229-A1 Sars-cov-2 test kit for rt-qpcr assays Pending 16-Apr-2020 000000000
CA-3175815-A1 Sars-cov-2 test kit for rt-qpcr assays Pending 16-Apr-2020 000000000
EP-4136229-A4 Sars-cov-2 test kit for rt-qpcr assays Pending 16-Apr-2020 000000000 0
EP-3494236-B1 Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence Active 05-Jan-2017 0000000000
EP-3494236-A4 Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence Active 05-Jan-2017 C12Q1/6886 0
To view DiaCarta’s complete patent history, request access »

DiaCarta Executive Team (9)

Name Title Board Seat Contact Info
Aiguo Zhang Ph.D Co-Founder, President & Chief Executive Officer
Michael Sha Ph.D Chief Technology Officer & Senior Vice President of Research & Development
Dennis Gao Vice President of Finance and Principle Financial Officer.
Paul Okunieff MD Co-Founder, Chief Medical Officer & Consultant
You’re viewing 4 of 9 executive team members. Get the full list »

DiaCarta Board Members (3)

Name Representing Role Since
Jack Kaye Self Board Member & Chairman 000 0000
Zhi Yang Ph.D BVCF Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

DiaCarta Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiaCarta Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Fortune Fountain Capital PE/Buyout Minority 000 0000 000000 0
Global Healthcare Capital Real Estate Minority 000 0000 000000 0
BVCF Venture Capital Minority 000 0000 000000 0
To view DiaCarta’s complete investors history, request access »

DiaCarta Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
HH&L Acquisition 30-Jun-2023 0000000000 00000 Special Purpose Acquisition Company (SPAC) 00000 000
To view DiaCarta’s complete acquisitions history, request access »

DiaCarta FAQs

  • When was DiaCarta founded?

    DiaCarta was founded in 2014.

  • Who is the founder of DiaCarta?

    Aiguo Zhang Ph.D and Paul Okunieff MD are the founders of DiaCarta.

  • Who is the CEO of DiaCarta?

    Aiguo Zhang Ph.D is the CEO of DiaCarta.

  • Where is DiaCarta headquartered?

    DiaCarta is headquartered in Pleasanton, CA.

  • What is the size of DiaCarta?

    DiaCarta has 49 total employees.

  • What industry is DiaCarta in?

    DiaCarta’s primary industry is Laboratory Services (Healthcare).

  • Is DiaCarta a private or public company?

    DiaCarta is a Private company.

  • What is DiaCarta’s current revenue?

    The current revenue for DiaCarta is 00000.

  • How much funding has DiaCarta raised over time?

    DiaCarta has raised $53M.

  • Who are DiaCarta’s investors?

    National Institutes of Health, Fortune Fountain Capital, Global Healthcare Capital, and BVCF have invested in DiaCarta.

  • Who are DiaCarta’s competitors?

    Igenomix, GeneCast Biotechnology, Ambry Genetics, Biodesix, and Biocept are some of the 51 competitors of DiaCarta.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »